U.S. employers added just 266,000 jobs in April

Economists were expecting 1 million.

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

10.42+0.13 (+1.26%)

As of 9:53AM EDT. Market open.

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	10.29
Open	10.21
Bid	10.39 x 900
Ask	10.40 x 1300
Day's Range	10.21 - 10.46
52 Week Range	8.44 - 13.30
Volume	634,820
Avg. Volume	9,525,954

Market Cap	11.542B
Beta (5Y Monthly)	1.47
PE Ratio (TTM)	N/A
EPS (TTM)	-3.63
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	Nov 27, 2017
1y Target Est	11.92

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

6% Est. Return

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Motley Fool
Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript
At this time, I'd like to turn the conference over to Atabak Mokari. Today, we issued three press releases, one announcing the positive outcome of our 178 patients Phase 2 trial of relacorilant in combination with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. Second, announcing markedly decreased liver fat in patients in our Phase 2 trial of miricorilant as a potential treatment for nonalcoholic steatohepatitis or NASH, and the third, providing a clinical update and announcing our financial results for the first quarter.
- Aaon Inc (AAON) Q1 2021 Earnings Call Transcript
  Motley Fool
- Guardant Health Inc (GH) Q1 2021 Earnings Call Transcript
  Motley Fool
Business Wire
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the company’s efforts to advance health and equity, minimize its impact on the planet and dedicate itself to quality, ethics and transparency.
- Fisker Launches New Resource for Environmental, Social, and Governance Policy, Practices and Reporting
  Business Wire
- Investing trends: why more people are looking into ESG opportunities
  Yahoo Finance Video
Business Wire
Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections, and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.